Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure. Aviptadil exerts anti‐inflammatory and cytoprotective effects on lung tissue, and Relief has partnered with U.S.-based NeuroRx, Inc. to advance late‐stage clinical programs and regulatory filings in North America. RLF-100 has received orphan drug designations in both the European Union and the United States.
Beyond its flagship program, Relief is advancing additional clinical and preclinical assets targeting fibrotic, inflammatory and endocrine disorders. The company has executed research collaborations and licensing agreements to broaden its pipeline, and it works with contract research organizations to conduct multi-center trials across Europe and the United States. Relief continues to explore VIP analogs and receptor‐targeted molecules for conditions such as pulmonary arterial hypertension and Duchenne muscular dystrophy.
Founded in 2016, Relief Therapeutics maintains operations in Geneva and has established a U.S. subsidiary to support its North American development strategy. The company’s leadership team brings experience from global biopharma and academic research, guiding a translational approach that spans discovery, clinical development and regulatory engagement. Relief Therapeutics is committed to delivering innovative treatments to patients suffering from life‐threatening and rare diseases worldwide.
AI Generated. May Contain Errors.
